Hainan Poly Pharm

Hainan Poly Pharm, established in 1992, is a key player in the Pharmaceuticals and Healthcare sectors, operating from its base in Haikou, Hainan, China. The company specializes in the comprehensive development and manufacturing of prescription and over-the-counter medications, active pharmaceutical ingredients (APIs), and offers custom services for drug formulation. Their integrated approach spans from initial research and development through to the commercialization of pharmaceutical products, serving both domestic Chinese and international markets.

With a significant operational footprint, Hainan Poly Pharm manages 7 locations and employs between 1,000 and 5,000 professionals. The company is dedicated to advancing innovative therapies, with notable projects in boron neutron capture therapy and synthetic biology, particularly targeting oncology and other critical therapeutic areas. This commitment to cutting-edge research aims to enhance existing treatment options. To understand the expertise driving these advancements, you can Meet Hainan Poly Pharm's team.

The company's market presence is further solidified by its listing under the ticker SSE: 300630 and a reported revenue of $245.6M. Hainan Poly Pharm has successfully registered a diverse portfolio of products, including various dosage forms, across numerous countries, demonstrating its global regulatory compliance and market penetration capabilities. Their strategic focus on innovation and quality manufacturing positions them to continue contributing to global health solutions.